In the present study, we demonstrated that cervical squamous cell carcinoma cell lines with EGFR amplification were more sensitive to a potent EGFR inhibitor AG1478, which suggests that TKI therapy may have some utility in cervical cancer tumours without mutations, provided that EGFR amplification is present. The gene discussed is EGFR; the disease is cervical squamous cell carcinoma.